Cancer Research and Treatment

Ex vivo liver resection and auto-transplantation and special systemic therapy in perihilar cholangiocarcinoma treatment

World Journal of Gastrointestinal Surgery.2024; 16(3): 635. CrossRef

The predictive value of PD-L1 expression in response to anti-PD-1/PD-L1 therapy for biliary tract cancer: a systematic review and meta-analysis

Seung Bae Yoon, Sang Myung Woo, Jung Won Chun, Dong Uk Kim, Jaihwan Kim, Joo Kyung Park, Hoonsub So, Moon Jae Chung, In Rae Cho, Jun Heo

Anti-PD-1-based immunotherapy plus lenvatinib to treat advanced gallbladder cancer in the elderly: a case series and review of current literature

Journal of Cancer Research and Clinical Oncology.2023; 149(3): 941. CrossRef

A prospective multicenter phase II study of FOLFIRINOX as a first-line treatment for patients with advanced and recurrent biliary tract cancer

Naminatsu Takahara, Yousuke Nakai, Hiroyuki Isayama, Takashi Sasaki, Yuji Morine, Kazuo Watanabe, Makoto Ueno, Tatsuya Ioka, Masashi Kanai, Shunsuke Kondo, Naohiro Okano, Kazuhiko Koike

Investigational New Drugs.2023; 41(1): 76. CrossRef

Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma

Jiajia Du, Xing Lv, Zunyi Zhang, Zhiyong Huang, Erlei Zhang

Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular–cholangiocarcinoma

Yoon Jung Jang, Eo Jin Kim, Hyung-Don Kim, Kyu-Pyo Kim, Min-Hee Ryu, Sook Ryun Park, Won-Mook Choi, Danbi Lee, Jonggi Choi, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Baek-Yeol Ryoo, Changhoon Yoo

Journal of Cancer Research and Clinical Oncology.2023; 149(10): 7547. CrossRef

Precision Medicine and Immunotherapy Have Arrived for Cholangiocarcinoma: An Overview of Recent Approvals and Ongoing Clinical Trials

Moving beyond single-agent checkpoint inhibition in biliary tract cancers: what is the next frontier?

Chemo-Free Treatment Using Anti-PD-1 Antibodies with Lenvatinib in Unresectable Gallbladder Cancer: PD-L1 May Be a Potential Biomarker for a Better Outcome

Tiantian Wu, Changsheng Pu, Xianjia Wu, Qiang Wang, Keming Zhang

Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis

Giorgio Frega, Fernando P. Cossio, Jesus M. Banales, Vincenzo Cardinale, Rocio I. R. Macias, Chiara Braconi, Angela Lamarca

Comparison of Efficacy and Safety of Anti-Programmed Cell Death-1 Antibody Plus Lenvatinib and Chemotherapy as First-Line Therapy for Patients with Stage IV Gallbladder Cancer: A Real-World Study in a Chinese Population

Tiantian Wu, Changsheng Pu, Qiang Wang, Keming Zhang

The Expression of Programmed Death-Ligand 1 on Immune Cells Is Related to a Better Prognosis in Biliary Tract Cancer

Sung Chan Kwon, Seungmin Bang, Young Nyun Park, Ji Hoon Park, So Jeong Kim, Jung Hyun Jo, Moon Jae Chung, Jeong Youp Park, Seung Woo Park, Si Young Song, Eunhyang Park, Hee Seung Lee

Equipoise, drug development, and biliary cancer

Tristan Y. Lee, Susan E. Bates, Ghassan K. Abou‐Alfa

Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications

Lionel A. Kankeu Fonkoua, Pedro Luiz Serrano Uson Junior, Kabir Mody, Amit Mahipal, Mitesh J. Borad, Lewis R. Roberts

Expert Opinion on Therapeutic Targets.2022; 26(1): 79. CrossRef

Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers

Yulong Zheng, Anna Rachelle Austria Mislang, Jermaine Coward, Rasha Cosman, Adam Cooper, Craig Underhill, Jianqing Zhu, Jianping Xiong, Ou Jiang, Hong Wang, Yanru Xie, Yuefen Zhou, Xiaoping Jin, Baiyong Li, Zhongmin Maxwell Wang, Kon Yew Kwek, Dennis Xia,

Cancer Immunology, Immunotherapy.2022; 71(10): 2371. CrossRef

Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis

Qi Jiang, Jinsheng Huang, Bei Zhang, Xujia Li, Xiuxing Chen, Bokang Cui, Shengping Li, Guifang Guo

Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy

Min Deng, Shaohua Li, Qiaoxuan Wang, Rongce Zhao, Jingwen Zou, Wenping Lin, Jie Mei, Wei Wei, Rongping Guo

Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses

Tao Xia, Keyu Li, Nan Niu, Yingkuan Shao, Ding Ding, Dwayne L. Thomas, Hao Jing, Kenji Fujiwara, Haijie Hu, Arsen Osipov, Chunhui Yuan, Christopher L. Wolfgang, Elizabeth D. Thompson, Robert A. Anders, Jin He, Yiping Mou, Adrian G. Murphy, Lei Zheng

Journal of Hematology & Oncology.2022;[Epub] CrossRef

Targeted Therapies for Perihilar Cholangiocarcinoma

Simon Gray, Angela Lamarca, Julien Edeline, Heinz-Josef Klümpen, Richard A. Hubner, Mairéad G. McNamara, Juan W. Valle

Novel Palliative Chemotherapy for Cholangiocarcinoma

The Korean Journal of Pancreas and Biliary Tract.2022; 27(2): 90. CrossRef

Advances in the systemic treatment of therapeutic approaches in biliary tract cancer

O. Mirallas, D. López-Valbuena, D. García-Illescas, C. Fabregat-Franco, H. Verdaguer, J. Tabernero, T. Macarulla

Aging and biliary tract cancers: Epidemiology, molecular biology, and clinical practice

Xiaoling Weng, Xiaoling Song, Rong Shao, Fatao Liu, Yingbin Liu

Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis

Xue-Gang Yang, Yan-Yuan Sun, De-Shan Li, Guo-Hui Xu, Xiao-Qi Huang

Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China

Changying Shi, Yulong Li, Cheng Yang, Liang Qiao, Liukang Tang, Yuting Zheng, Xue Chen, Youwen Qian, Jiamei Yang, Dong Wu, Feng Xie

Immunotherapy in biliary tract cancers: Current evidence and future perspectives

World Journal of Gastrointestinal Oncology.2022; 14(8): 1446. CrossRef

Immune Checkpoint Inhibitors for Advanced Biliary Tract Cancer

Current Cancer Drug Targets.2022; 22(8): 639. CrossRef

Safety and Efficacy of Allogeneic Natural Killer Cells in Combination with Pembrolizumab in Patients with Chemotherapy-Refractory Biliary Tract Cancer: A Multicenter Open-Label Phase 1/2a Trial

Galam Leem, Sung-Ill Jang, Jae-Hee Cho, Jung Hyun Jo, Hee Seung Lee, Moon Jae Chung, Jeong Youp Park, Seungmin Bang, Da-Kyung Yoo, Hyo-Cheon Cheon, Jae-Eun Kim, Kyeong-Pill Lim, In-Hye Jung, Jung-Min Im, Yong-Yoon Chung, Seung Woo Park

Prognostic Factors in Patients Treated with Pembrolizumab as a Second-Line Treatment for Advanced Biliary Tract Cancer

Chan Su Park, Min Je Sung, So Jeong Kim, Jung Hyun Jo, Hee Seung Lee, Moon Jae Chung, Seungmin Bang, Seung Woo Park, Si Young Song, Jeong Youp Park

The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study

Peixin Huang, Xiaoyong Huang, Yingting Zhou, Guohuan Yang, Qiman Sun, Guoming Shi, Yi Chen, Quirino Lai

Canadian Journal of Gastroenterology and Hepatology.2022; 2022: 1. CrossRef

PD-1 inhibitors plus nab-paclitaxel-containing chemotherapy for advanced gallbladder cancer in a second-line setting: A retrospective analysis of a case series

Sirui Tan, Jing Yu, Qiyue Huang, Nan Zhou, Hongfeng Gou

Treating Biliary Tract Cancers: New Targets and Therapies

Immunotherapies in clinical development for biliary tract cancer

Expert Opinion on Investigational Drugs.2021; 30(4): 351. CrossRef

Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3- CD4+ T Cells in Biliary Tract Cancer

Hyung-Don Kim, Jwa Hoon Kim, Yeon-Mi Ryu, Danbee Kim, Sunmin Lee, Jaehoon Shin, Seung-Mo Hong, Ki-Hun Kim, Dong‐Hwan Jung, Gi‐Won Song, Dae Wook Hwang, Jae Hoon Lee, Ki Byung Song, Baek-Yeol Ryoo, Jae Ho Jeong, Kyu-pyo Kim, Sang-Yeob Kim, Changhoon Yoo

Cancer Research and Treatment.2021; 53(1): 162. CrossRef

Clinically significant genomic alterations in the Chinese and Western patients with intrahepatic cholangiocarcinoma

Shifeng Xu, Yuan Guo, Yanwu Zeng, Zhijian Song, Xiaodan Zhu, Ning Fan, Zhilei Zhang, Guibing Ren, Yunjin Zang, Wei Rao

Successful pembrolizumab treatment of microsatellite instability‐high intrahepatic cholangiocarcinoma: A case report

Yuki Ikeda, Michihiro Ono, Ginji Ohmori, Saki Ameda, Michiko Yamada, Tomoyuki Abe, Shigeyuki Fujii, Miri Fujita, Masahiro Maeda

Horizons on the Therapy of Biliary Tract Cancers: A State-of-the-art Review

Ran Xue, Rong Li, Jianxin Wang, Weiping Tong, Jianyu Hao

Journal of Clinical and Translational Hepatology.2021; 000(000): 000. CrossRef

An Assessment of Combination of the Camrelizumab With Chemotherapy in Metastatic Biliary Tract Cancers

Yi Yu, Shanshan Huang, Jun Chen, Feng Yu, Lin Zhang, Xiaojun Xiang, Jun Deng, Ziling Fang, Junhe Li, Jianping Xiong

Cancer Control.2021; 28: 107327482110171. CrossRef

Gastrointestinal cancer treatment with immune checkpoint inhibitors

Journal of the Korean Medical Association.2021; 64(5): 342. CrossRef

Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers

Kwang-Yu Chang, Nai-Jung Chiang, Shang-Yin Wu, Chia-Jui Yen, Shang-Hung Chen, Yu-Min Yeh, Chien-Feng Li, Xiaoxing Feng, Katherine Wu, Amanda Johnston, John S. Bomalaski, Bor-Wen Wu, Jianjun Gao, Sumit K. Subudhi, Ahmed O. Kaseb, Jorge M. Blando, Shalini S

A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy

In Sil Choi, Ki Hwan Kim, Ju Hyun Lee, Koung Jin Suh, Ji-Won Kim, Jin Hyun Park, Yu Jung Kim, Jin-Soo Kim, Jee Hyun Kim, Jin Won Kim

European Journal of Cancer.2021; 154: 288. CrossRef

IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer

Stephen P. Hack, Wendy Verret, Sohail Mulla, Bo Liu, Yulei Wang, Teresa Macarulla, Zhenggang Ren, Anthony B. El-Khoueiry, Andrew X. Zhu

Therapeutic Advances in Medical Oncology.2021; 13: 175883592110365. CrossRef

Case Report: Response With Immunotherapy in a Patient With Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gallbladder

Chao Liu, Xiangwei Hua, Zhen Yang, Yuan Guo, Liqun Wu, Jinzhen Cai, Ling Li, Yaxuan Zhang, Ning Fan

Durable response of immune checkpoint inhibitor after failure of gemcitabine-based chemotherapy for a patient with metastatic biliary tract cancer

Journal of Cancer Research and Practice.2021; 8(4): 152. CrossRef

Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study

Sang Hoon Lee, Hee Seung Lee, Sang Hyub Lee, Sang Myung Woo, Dong Uk Kim, Seungmin Bang

Journal of Clinical Medicine.2020; 9(6): 1769. CrossRef

Systemic treatment of advanced or recurrent biliary tract cancer

Wei Zhang, Hongyuan Zhou, Yingying Wang, Zewu Zhang, Guangtai Cao, Tianqiang Song, Ti Zhang, Qiang Li

Overview of current targeted therapy in gallbladder cancer

Xiaoling Song, Yunping Hu, Yongsheng Li, Rong Shao, Fatao Liu, Yingbin Liu

Signal Transduction and Targeted Therapy.2020;[Epub] CrossRef